OSCR
Oscar Health, Inc.
OSCR has the edge over ZBH overall, supported by stronger fundamentals and stronger modeled upside.
ZBH
Zimmer Biomet Holdings, Inc.
ZBH has lower modeled downside risk, despite its lower overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZBH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Strong | |
| Under pressure |
ZBH's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ZBH in the historical PE scenario, which offers more potential upside but is not a forecast.
ZBH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $105 | — |
| Cheap | 22x | $87.95 | -16% |
| Current | 26x | $105 | — |
| Fair | 31x | $123 | +18% |
| Expensive | 94x | $371 | +255% |
Historical ranges are pointers, not guarantees.
ZBH's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ZBH on the outlook, with more favorable revenue expectations.
ZBH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Stable | |
| Improving | |
| Moderate | |
| High |
Analysts expect ZBH's earnings to grow and its profitability to improve, with its revenue holding steady.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over ZBH on earnings, with more consistent year-over-year improvement.
ZBH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.82 | +123% |
| Q3 2026 | $3.96 | -1.5% |
| Q2 2026 | $4.12 | +0.7% |
| Q1 2026 | $3.86 | -14% |
| Q4 2025 | $3.55 | -20% |
| Q3 2025 | $4.02 | -23% |
| Q2 2025 | $4.09 | -15% |
| Q1 2025 | $4.50 | -2.4% |
| Q4 2024 | $4.43 | -9.2% |
ZBH's earnings per share have fallen from their peak: $3.96 over the past year, against $5.31 in late 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ZBH on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ZBH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.1B | +3.1% |
| Q2 2026 | $2.2B | +4.8% |
| Q1 2026 | $2.1B | +9.3% |
| Q4 2025 | $2.2B | +11% |
| Q3 2025 | $2B | +9.7% |
| Q2 2025 | $2.1B | +7% |
| Q1 2025 | $1.9B | +1.1% |
| Q4 2024 | $2B | +4.3% |
ZBH's revenue has grown year over year for 15 quarters in a row: $2.1B last quarter, up 3.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | -2.6 points |
| Q2 2026 | 15% | +0.5 points |
| Q1 2026 | 18% | +2.6 points |
| Q4 2025 | 6.9% | -12 points |
| Q3 2025 | 18% | +2.2 points |
| Q2 2025 | 14% | -3.7 points |
| Q1 2025 | 15% | +1.2 points |
| Q4 2024 | 19% | +1 points |
ZBH has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ZBH on cash flow, with more consistent year-over-year improvement.
ZBH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $484.2M | +33% |
| Q2 2026 | $393.6M | +20% |
| Q1 2026 | $323.1M | -4.5% |
| Q4 2025 | $442.6M | -2.7% |
| Q3 2025 | $363.7M | +3.6% |
| Q2 2025 | $328.1M | +3.6% |
| Q1 2025 | $338.2M | +96% |
| Q4 2024 | $454.8M | -13% |
ZBH generated $1.6B in free cash flow over the past year, up 11% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ZBH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.7% | -1.4M shares |
| 1 year | -3.7% | -7.4M shares |
| 3 years | -8.9% | -18.6M shares |
| 5 years | -12% | -25.5M shares |
| Available history | -10% | -21.5M shares |
ZBH has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $78.5M |
| Q2 2026 | $250.7M |
| Q1 2026 | $250.1M |
| Q4 2025 | $250M |
| Q3 2025 | — |
| Q2 2025 | $7.2M |
| Q1 2025 | $229.8M |
| Q4 2024 | $72.2M |
ZBH spent $829M buying back its own shares over the past year, up 168% from the year before.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ZBH on leverage, with a lower net debt burden relative to earnings.
ZBH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.1x | Elevated |
| Q4 2025 | 3.2x | Elevated |
| Q3 2025 | 2.8x | Moderate |
| Q2 2025 | 3.1x | Elevated |
| Q1 2025 | 2.5x | Moderate |
| Q4 2024 | 2.5x | Moderate |
ZBH's net debt is about 3.1 years of its operating earnings (EBITDA), up from 2.8 years a year ago.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ZBH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.1 | Neutral |
| Stochastic | 62.8 | Neutral |
ZBH's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ZBH on valuation relative to its sector.
ZBH PE vs Healthcare Sector
| Metric | ZBH | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | 2.1% above |
| PE % | 45 | 29 | 16 pts above |
ZBH is trading at 26x earnings, in line with the Healthcare sector's median of 26x.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ZBH on trend strength, trading above more of its moving averages.
ZBH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $95.8 | 9.1% above |
| 20 week MA | $95.4 | 9.6% above |
| 50 week MA | $92.2 | 13% above |
| 100 week MA | $96.3 | 8.6% above |
| 200 week MA | $108.2 | 3.4% below |
ZBH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 3.4% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ZBH on returns for 2026, with the stronger performance.
ZBH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $145.5 | $144.8 | -0.5% |
| 2021 | $144.8 | $123.2 | -15% |
| 2022 | $123.2 | $126.7 | +2.8% |
| 2023 | $126.7 | $121.7 | -3.9% |
| 2024 | $121.7 | $106.9 | -12% |
| 2025 | $106.9 | $90.8 | -15% |
| 2026 YTD | $90.8 | $104.6 | +15% |
ZBH has finished three years in a row lower, and it's up 15% so far in 2026.